Alnylam Pharmaceuticals | ALNY - Loan Capital

Stock Price
321.18
Daily Change
-6.07 -1.85%
Monthly
-0.37%
Yearly
41.94%
Q2 Forecast
309.25

Alnylam Pharmaceuticals reported $2.48B in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
Arrowhead Research USD 538.1M 323.22M Dec/2025
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Moderna USD 610M 584M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 29.59B 5.35B Dec/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 15.72B 150.06M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Takeda JPY 4.27T 81.29B Dec/2025
Tectonic Therapeutic USD 43K 57K Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025
Xencor USD 76.48M 11.29M Dec/2025